source
- Werewolf transforms into Ambros via reverse merger to support phase 3 push for rare disease drugWerewolf Therapeutics’ hunt for strategic alternatives has ended. Ambros Therapeutics has agreed to merge with Werewolf in an all-stock deal and raised $150 million, positioning the biotech to take…Fierce Biotech · 7h ago↗ source
- FDA clears Vitestro's Aletta, first robotic blood draw device for U.S. clinicsThe U.S. Food and Drug Administration has granted clearance to Vitestro's Aletta, making it the first standalone robotic system approved to draw blood without direct human handling. Aletta can per…